Navigation Links
Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
Date:5/6/2013

NESS ZIONA, Israel, May 6, 2013 /PRNewswire/ --

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for a long acting depot formulation of glatiramer acetate. The formulation is under development as a once-a-month treatment for Multiple Sclerosis (MS). The existing glatiramer acetate dosage form on the market today requires daily administrations (by injection).

US Patent number 8,377,885 B2 is titled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof. The glatiramer acetate depot formulation described therein is to be injected once-a-month under the skin or into a muscle for a prolonged release of the therapeutic agent.

"It is a bright day both for MS patients and Mapi Pharma. Today's news strengthens Mapi's patent position, supports its business plan and advances the company one step closer to bringing MS patients an improved drug to be administered once-a-month," said Mapi Pharma President & CEO Mr. Ehud Marom .

MS is a chronic, often disabling disease that attacks the central nervous system. Symptoms include numbness in the limbs, paralysis and loss of vision. Symptoms are unpredictable and differ from one person to another. The global market for MS pharmaceuticals is estimated to be approximately US $10 billion.

About Mapi-Pharma

Mapi Pharma (Mapi) is an international pharmaceutical company specializing in complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high development barrier generics and novel finished dosage forms based on selected drug delivery systems. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relationships in all of the countries in which it is present. Mapi is dedicated to providing generic and innovative intermediates & APIs as well as developing finished dosage forms - either to Mapi's internal API program, as a vertically integrated company, or generic, to other leading brands. Mapi is headquartered in Israel.  It has R&D facilities in Israel, China and Germany and is currently building an API manufacturing site in Neot Hovav, Israel's designated chemical park. The company has a strong IP position, filing more than 20 patent applications for APIs and formulations in less than three years of operation. For more information: http://www.mapi-pharma.com.

Press Contact:
Marjie Hadad
Media Liaison
Mapi Pharma
marjie@mapi-pharma.com
+972-54-536-5220


'/>"/>
SOURCE Mapi Pharma Ltd. (Mapi)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
2. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
3. Valeant Pharmaceuticals Provides Efinconazole Update
4. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
5. Cumberland Pharmaceuticals Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
7. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
8. 2013 Pharmaceutical Drug Naming Trends
9. SynteractHCR Addressing Successful Ways to Approach Sponsor and CRO Collaboration at May Pharmaceutical Events in US and Europe
10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
11. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the Cowen and Company 37 th Annual ... on Tuesday, March 7, 2017 at 11:20 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
(Date:2/24/2017)... Feb. 24, 2017 Medical information groups ... increase their self-service capabilities to manage inquiries from ... New research from consulting leader Best ... developed self-service website portals where HCPs can sign ... one of many findings to emerge from the ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... This ... laser diffraction analysis as a tool to characterize particle size distributions in the ... obtain improved results and novel scientific findings. It describes methods of optimized and ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ... 2017 , ... ODH, Inc.™ announced today it will exhibit and speak ... City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will ... Medicaid population health management. , ODH will also have an exhibit booth where attendees ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... promotions on tooth replacement options at his office, Antoine Dental Center. Currently, patients ... for $18,499. Some restrictions may apply, but patients can learn more about these ...
Breaking Medicine News(10 mins):